PATENT COOPERATION TREATY

PCT

REC'D	28	FEB	2005
WIPO			PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 4 -32801A	FOR FURTHER ACTION See Form PCT/IPEA/416							
International application No.	International filing date (day/mo							
PCT/EP2004/003510	02.04.2004	04.04.2003						
International Patent Classification (IPC) or national classification and IPC A61K31/436, A61P31/04								
Applicant NOVARTIS AG et al.								
Authority under Article 35 and tra	nsmitted to the applicant acco							
2. This REPORT consists of a total	of 5 sheets, including this cov	ver sheet.						
3. This report is also accompanied								
a. 🛭 sent to the applicant and	to the International Bureau) a t	total of sheets, as follows:						
and/or sheets contair Administrative Instruc	The second secon							
☐ sheets which superson beyond the disclosur Supplemental Box.	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the							
 b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions). 								
4. This report contains indications	elating to the following items:							
☐ Box No. I Basis of the o	inion							
☐ Box Nor II Priority								
	ment of opinion with regard to	novelty, inventive step and industrial applicability						
☐ Box No. IV Lack of unity of								
applicability; c	and the second s							
☐ Box No. VI Certain docum								
	s in the international application							
☐ Box No. VIII Certain obser	☐ Box No. VIII Certain observations on the international application							
Date of submission of the demand	Dat	e of completion of this report						
Date of debiniosion of the definance								
14.10.2004	25.	02.2005						
Name and mailing address of the internati preliminary examining authority:	onal Aut	horized Officer						
European Patent Office	Ec	onomou, D						
Tel. +49 89 2399 - 0 Tx: 52 Fax: +49 89 2399 - 4465	3656 epmu a . Tel	ephone No. +49 89 2399-8599						

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/003510

	Box	No. I Basis of the report				
1.	With regard to the language , this report is based on the international application in the language in which it filed, unless otherwise indicated under this item.					
		This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:				
		 □ international search (under Rules 12.3 and 23.1(b)) □ publication of the international application (under Rule 12.4) □ international preliminary examination (under Rules 55.2 and/or 55.3) 				
2.	2. With regard to the elements* of the international application, this report is based on (replacement sheets wh have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):					
	Des	cription, Pages				
	1-12	as originally filed				
	Clai	ms, Numbers				
	1-6	as originally filed				
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing				
3.		The amendments have resulted in the cancellation of: ☐ the description, pages ☐ the claims, Nos.				
		the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify):				
4.	□ had Sup	This report has been established as if (some of) the amendments annexed to this report and listed below not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the plemental Box (Rule 70.2(c)).				
		☐ the description, pages ☐ the claims, Nos.				
		☐ the drawings, sheets/figs ☐ the sequence listing (specify):				
		☐ any table(s) related to sequence listing (specify):				
	*	If item 4 applies, some or all of these sheets may be marked "superseded."				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/003510

		No. III Non-establishment o	f opii	nion with regard to novelty, inventive step and industrial		
1.	The obv	questions whether the claimed i ious), or to be industrially applica	estions whether the claimed invention appears to be novel, to involve an inventive step (to be non- s), or to be industrially applicable have not been examined in respect of:			
		the entire international application	on,			
	\boxtimes	claims Nos. 3				
		because:				
	×	the said international application, or the said claims Nos. 3 with regard to IA (see separate sheet, item 1a) relate to the following subject matter which does not require an international preliminary examination (specify):				
	see separate sheet					
		the description, claims or drawi that no meaningful opinion coul	he description, claims or drawings <i>(indicate particular elements below)</i> or said claims Nos. are so unclear hat no meaningful opinion could be formed <i>(specify)</i> :			
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
		·		does not comply with the standard		
		the tables related to the nucleon not comply with the technical r	otide a equir	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C- <i>bis</i> of the Administrative Instructions.		
		See separate sheet for further	detai	ils		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/003510

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No: Claims

1-6 (see separate sheet, item 2).

Inventive step (IS)

Yes: Claims

No: Claims

Industrial applicability (IA)

Yes: Claims

1-2, 4-6 (see separate sheet, item 1c); 3 (see separate

sheet, items 1a and 1b)

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VI Certain documents cited

1. Certain published documents (Rule 70.10)

and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

PCT/EP2004/003510

- a). Claim 3 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(l) PCT).
 - b). For the assessment of the present claim 3 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.
 - c). The subject-matter of claims 1-2 and 4-6 fulfils the requirements of industrial applicability.
- D1 (=WO 02/098376) discloses compositions comprising immunosuppressant macrolide compound, inter alia pimecrolimus, in combination with antibacterials and retinoids for the treatment of acne (see the passages cited in the ISR). Hence, the subject-matter of claims 1 and 3-6 is not novel.
 - **D2** (=US 2003/021816) discloses compositions comprising immunosuppressant macrolide compound, inter alia pimecrolimus, in combination with antibacterials and retinoids for the treatment of acne (see the passages cited in the ISR). Hence, the subject-matter of claims 1 and 3-6 is not novel.
 - **D3** (=WO 02/089796) discloses combinations of pimecrolimus with sulfasalazine or ciprofloxacin for the treatment of IBD (see the passages cited in the ISR). Hence ,the subject-matter of clams 1-6 is not novel.
- -3). Should the application enter the European Phase the-subject-matter of **D4** (=WO 03/092702; Publ. date: 13.11.2003; Priority date: 02.05.2002; Filing date: 02.05.2003) would be prejudicial to the novelty of the subject-matter of the present application.